Categorization and complication of non-alcoholic fatty liver disease

Authors

  • Samar A. Alharbi Department of Internal Medicine, Al Thager Hospital, Jeddah, Saudi Arabia
  • Ammar H. Alhayki General Physician, Alnabaa Medical Center, Aali, Bahrain
  • Ahmed A. Alghamdi College of Medicine, University of Bisha, Bisha, Saudi Arabia
  • Abdulrahman S. Althobaiti College of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
  • Fatema F. Alkhalfan College of Medicine, Arabian Gulf University, Manama, Bahrain
  • Nawaf A. Muaddi College of Medicine, University of Bisha, Bisha, Saudi Arabia
  • Mohammad S. Almabouth Department of Emergency Medicine, Al Noor Specialist Hospital, Mecca, Saudi Arabia
  • Zainab M. Alfaraj Department of Internal Medicine, Eradah Mental Health Complex, Al-Khobar, Saudi Arabia
  • Mohammed H. Almajed College of Medicine, King Saud University, Riyadh, Saudi Arabia
  • Ali A. Alkhiri Department of Internal Medicine, Al Mozeilef General Hospital, Al Qunfudah, Saudi Arabia
  • Basmah A. Altharmani College of Medicine, Ibn Sina National College, Jeddah, Saudi Arabia

DOI:

https://doi.org/10.18203/2394-6040.ijcmph20223578

Keywords:

Non-alcoholic, Fatty, Liver, Steatohepatitis

Abstract

Non-alcoholic fatty liver disease is the most prevalent liver disease with a global prevalence of 25%. The frequency of non-alcoholic fatty liver disease and the percentage of people with severe liver disease are expected to rise given the ongoing obesity pandemic, the rise in diabetes, and other factors. This will have a significant effect on health care expenditure and the need for liver transplantation, for which non-alcoholic steatohepatitis is already on track to overtake alcoholic steatohepatitis as the most prevalent reason. Non-alcoholic fatty liver disease is characterized by the triglyceride accumulation in the cytoplasm of hepatocytes. Patients with non-alcoholic fatty liver disease who have advanced fibrosis and non-alcoholic steatohepatitis are at much higher risk of negative outcomes, such as overall mortality and liver-specific morbidity and death. It is a multisystemic clinical illness entity that manifests extrahepatic conditions like polycystic ovarian syndrome, type 2 diabetes, chronic renal disease, hypothyroidism, and psoriasis. In fact, cardiovascular disease, cancer, and liver-related problems are the three leading causes of death in non-alcoholic fatty liver disease patients, in that order. Non-alcoholic fatty liver disease is further divided into two subtypes hepatic steatosis and non-alcoholic steatohepatitis ranging from milder to more aggressive form of the disease.

References

Hashimoto E, Tokushige K, Ludwig J. Diagnosis and classification of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Current concepts and remaining challenges. Hepatol Res. 2015;45(1):20-8.

Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021;397(10290):2212-24.

Nd AM. Non-Alcoholic Fatty Liver Disease, an Overview. Integ Med (Encinitas, Calif). 2019;18(2):42-9.

Wang XJ, Malhi H. Nonalcoholic Fatty Liver Disease. Ann Int Med. 2018;169(9):65-80.

Pouwels S, Sakran N, Graham Y, Leal A, Pintar T, Yang W, et al. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. BMC Endocr Disord. 2022;22(1):63.

Tomeno W, Imajo K, Takayanagi T, Ebisawa Y, Seita K, Takimoto T, et al. Complications of Non-Alcoholic Fatty Liver Disease in Extrahepatic Organs. Diagnostics (Basel, Switzerland). 2020;10(11).

Tomic D, Kemp WW, Roberts SK. Nonalcoholic fatty liver disease: current concepts, epidemiology and management strategies. Eur J Gastroenterol Hepatol. 2018;30(10):1103-15.

Mantovani A, Scorletti E, Mosca A, Alisi A, Byrne CD, Targher G. Complications, morbidity and mortality of nonalcoholic fatty liver disease. Metab Clin Exp. 2020;111s:154170.

Perla FM, Prelati M, Lavorato M, Visicchio D, Anania C. The Role of Lipid and Lipoprotein Metabolism in Non-Alcoholic Fatty Liver Disease. Children (Basel, Switzerland). 2017;4(6).

Fabbrini E, Mohammed BS, Magkos F, Korenblat KM, Patterson BW, Klein S. Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. Gastroenterology. 2008;134(2):424-31.

Muthiah MD, Sanyal AJ. Current management of non-alcoholic steatohepatitis. Liver Int. 2020;40(1):89-95.

Heyens LJM, Busschots D, Koek GH, Robaeys G, Francque S. Liver Fibrosis in Non-alcoholic Fatty Liver Disease: From Liver Biopsy to Non-invasive Biomarkers in Diagnosis and Treatment. Front Med. 2021;8:615978.

Schwabe RF, Tabas I, Pajvani UB. Mechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis. Gastroenterology. 2020;158(7):1913-28.

Taylor RS, Taylor RJ, Bayliss S, Hagström H, Nasr P, Schattenberg JM, et al. Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Gastroenterology. 2020;158(6):1611-25.

Sanyal AJ, Van Natta ML, Clark J, Neuschwander-Tetri BA, Diehl A, Dasarathy S, et al. Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease. N Engl J Med. 2021;385(17):1559-69.

Ginès P, Krag A, Abraldes JG, Solà E, Fabrellas N, Kamath PS. Liver cirrhosis. Lancet. 2021;398(10308):1359-76.

Golabi P, Rhea L, Henry L, Younossi ZM. Hepatocellular carcinoma and non-alcoholic fatty liver disease. Hepatol Int. 2019;13(6):688-94.

Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut. 2020;69(9):1691-705.

Tana C, Ballestri S, Ricci F, i Vincenzo A, Ticinesi A, Gallina S, Giamberardino MA, et al. Cardiovascular Risk in Non-Alcoholic Fatty Liver Disease: Mechanisms and Therapeutic Implications. Int J Environ Res Public Health. 2019;16(17).

Targher G, Chonchol MB, Byrne CD. CKD and nonalcoholic fatty liver disease. Am J Kidney Dis. 2014;64(4):638-52.

Wijarnpreecha K, Panjawatanan P, Thongprayoon C, Jaruvongvanich V, Ungprasert P. Association between gastroesophageal reflux disease and nonalcoholic fatty liver disease: A meta-analysis. Saudi J Gastroenterol. 2017;23(6):311-7.

Allen AM, Hicks SB, Mara KC, Larson JJ, Therneau TM. The risk of incident extrahepatic cancers is higher in non-alcoholic fatty liver disease than obesity - A longitudinal cohort study. J Hepatol. 2019;71(6):1229-36.

Sanna C, Rosso C, Marietti M, Bugianesi E. Non-Alcoholic Fatty Liver Disease and Extra-Hepatic Cancers. Int J Mol Sci. 2016;17(5).

Downloads

Published

2022-12-29

How to Cite

Alharbi, S. A., Alhayki, A. H., Alghamdi, A. A., Althobaiti, A. S., Alkhalfan, F. F., Muaddi, N. A., Almabouth, M. S., Alfaraj, Z. M., Almajed, M. H., Alkhiri, A. A., & Altharmani, B. A. (2022). Categorization and complication of non-alcoholic fatty liver disease. International Journal Of Community Medicine And Public Health, 10(1), 486–490. https://doi.org/10.18203/2394-6040.ijcmph20223578

Issue

Section

Review Articles